Welcome to our dedicated page for Pds Biotechnology news (Ticker: PDSB), a resource for investors and traders seeking the latest updates and insights on Pds Biotechnology stock.
PDS Biotechnology Corporation reports developments in targeted cancer immunotherapies based on its Versamune platform. Company news centers on PDS0101, also called Versamune HPV, in HPV16-positive head and neck cancer, and on PDS01ADC, an IL-12 fused antibody drug conjugate and tumor-targeted immunocytokine evaluated across multiple solid tumor indications.
Recurring updates include clinical-trial data, National Cancer Institute-led study presentations, FDA and IND protocol communications, scientific publications, patent coverage for core technology, quarterly financial results, and broader corporate-program updates.
PDS Biotechnology Corporation (PDSB), a clinical-stage immunotherapy firm, announced on October 19, 2021, the granting of nonstatutory stock options to key personnel including CFO Matthew Hill and others. The options allow the purchase of shares at an exercise price of $12.03, based on the stock's closing price on the grant date. Each option vests over four years, promoting long-term employment. The company focuses on developing cancer immunotherapies utilizing its Versamune® technology, aiming to enhance T-cell responses against various cancers.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced a temporary suspension of recruitment in the Phase 2 clinical trial (NCT04287868) for PDS0101, evaluating its potential in advanced HPV cancers. This decision is not due to safety or efficacy concerns but rather administrative issues. The National Cancer Institute expects the recruitment to resume shortly without affecting the clinical data timeline. Interim data suggests PDS0101 may significantly improve outcomes for patients with limited options.
PDS Biotechnology Corporation (Nasdaq: PDSB) plans to release its third-quarter 2021 financial results on November 10, 2021, before market opening. Following the release, management will conduct a conference call at 8:00 am ET to discuss the results and provide a business update. PDS Biotech focuses on developing innovative cancer therapies using its proprietary Versamune® T-cell activating technology, targeting various cancers like breast and lung. The conference call can be accessed via phone or a live webcast on the company's investor relations page.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced Matthew Hill as the new Chief Financial Officer, effective October 18, 2021. Hill, with over 25 years of experience in finance within life sciences, previously held the CFO role at Strata Skin Sciences. He aims to guide PDS Biotech's financial strategy in a critical growth phase, especially with its proprietary Versamune® technology for cancer therapies. The company acknowledges the contribution of outgoing CFO Seth Van Voorhees. PDS Biotech focuses on developing innovative cancer treatments targeting several cancer types.
PDS Biotechnology Corporation (Nasdaq: PDSB) has completed enrollment for the first stage of the checkpoint inhibitor naïve arm in its VERSATILE-002 Phase 2 study targeting recurrent HPV16-associated head and neck cancer. This ambitious trial aims to assess the efficacy of PDS0101, in collaboration with Merck & Co. A significant milestone was achieved as objective response will be evaluated based on tumor reduction. If four out of the first 17 patients show positive results, the study will progress to the second stage involving 54 additional patients.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced its participation in the Benzinga Healthcare Small Cap Conference on September 29-30, 2021. The company will update on three ongoing PDS0101 Phase 2 clinical trials and progress on PDS0102 and PDS0103 into human clinical trials. CEO Dr. Frank Bedu-Addo will also join an oncology panel discussion. The company’s innovative Versamune® technology aims to enhance T-cell responses against various cancers. Investors can register online for the event and access a webcast replay post-conference.
PDS Biotechnology Corporation (Nasdaq: PDSB) will present at the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27-30, 2021. The presentation on September 28 at 4:40 PM EDT will cover updates on three ongoing Phase 2 clinical trials for PDS0101, along with advancements for investigational products PDS0102 and PDS0103. Following the conference, a replay will be available on the company's website. PDS Biotech focuses on cancer therapies utilizing its Versamune® T-cell activating technology.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced that its VERSATILE-002 Phase 2 study for treating advanced HPV16-associated head and neck cancer reached a preliminary safety benchmark. No dose-limiting toxicities were observed in the initial 12 patients. The trial will continue enrollment for efficacy evaluation among 17 checkpoint inhibitor (CPI) naïve patients and 21 CPI refractory patients. The study aims to advance based on tumor response criteria. PDS0101, in combination with KEYTRUDA, targets an unmet medical need in advanced cancer treatment.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced an equity award to Gregory Reid, its new VP of Program Development, as an inducement for joining the company. This award includes 63,800 shares with an exercise price of $14.99, vesting over four years. Reid brings over 30 years of pharmaceutical industry experience, particularly in oncology product development. His expertise aims to advance PDS Biotech's innovative cancer immunotherapy pipeline, leveraging its proprietary Versamune® technology, which targets various cancers effectively.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced its participation in the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit from September 21-23, 2021. The management will present updates on three ongoing Phase 2 clinical trials for PDS0101 and developments of PDS0102 and PDS0103 in human clinical trials. The presentation is scheduled for September 21, 2021, at 3:45 PM EDT. A webcast will follow on the company's investor website. PDSB focuses on innovative cancer therapies utilizing its proprietary Versamune® T-cell activating technology.